Hsiao-Sheng Liu

Title: Hsiao-Sheng Liu: Innovator in Colorectal Cancer Prognosis

Introduction

Hsiao-Sheng Liu is a prominent inventor based in Tainan, Taiwan. He has made significant contributions to the field of cancer research, particularly in the prognosis of colorectal cancer. With a total of 3 patents to his name, Liu's work is recognized for its innovative approaches to cancer diagnostics and treatment.

Latest Patents

One of Liu's latest patents is focused on a biomarker for the prognosis of colorectal cancer. This patent provides a method for accurate and sensitive characterization and prognosis of colorectal cancer in a subject. The method involves obtaining cancer tissue from the subject and determining the expression level of a miRNA and a target gene of the miRNA. Additionally, Liu has developed a kit for the prognosis of colorectal cancer in subjects who require it. Another significant patent by Liu is related to a regulator and pharmaceutical composition that encompasses the regulator. This disclosure is directed towards a regulator that modulates the expression of integrins and/or EMP2, which is employed for treating integrins-associated and/or EMP2-associated diseases.

Career Highlights

Throughout his career, Hsiao-Sheng Liu has worked with esteemed institutions such as National Cheng-Kung University and the National Science Council. His research has been pivotal in advancing the understanding of cancer biomarkers and therapeutic targets.

Collaborations

Liu has collaborated with notable colleagues, including Nan-Haw Chow and Wen-Tsan Chang, contributing to a rich environment of innovation and research.

Conclusion

Hsiao-Sheng Liu's contributions to cancer research, particularly in colorectal cancer prognosis, highlight his role as an influential inventor. His patents reflect a commitment to improving diagnostic methods and treatment options for patients.